Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SONN Sonnet BioTherapeutics Holdings, Inc. daily Stock Chart
SONN [NASD]
Sonnet BioTherapeutics Holdings, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-54.99 Insider Own7.60% Shs Outstand11.91M Perf Week-21.17%
Market Cap38.59M Forward P/E- EPS next Y-0.93 Insider Trans0.00% Shs Float8.51M Perf Month-4.99%
Income-17.20M PEG- EPS next Q- Inst Own0.50% Short Float6.54% Perf Quarter-31.65%
Sales28.00M P/S1.38 EPS this Y-23.90% Inst Trans415.58% Short Ratio0.20 Perf Half Y-78.96%
Book/sh-8.73 P/B- EPS next Y- ROA- Target Price- Perf Year-82.90%
Cash/sh0.04 P/C77.18 EPS next 5Y- ROE- 52W Range2.52 - 54.60 Perf YTD-78.88%
Dividend- P/FCF- EPS past 5Y22.30% ROI-436.50% 52W High-94.07% Beta1.05
Dividend %- Quick Ratio0.10 Sales past 5Y0.20% Gross Margin6.80% 52W Low28.57% ATR0.56
Employees587 Current Ratio0.10 Sales Q/Q-26.90% Oper. Margin- RSI (14)47.54 Volatility10.67% 15.41%
OptionableNo Debt/Eq- EPS Q/Q67.70% Profit Margin- Rel Volume0.34 Prev Close3.38
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.73M Price3.24
Recom2.00 SMA200.67% SMA50-10.57% SMA200-70.32% Volume939,922 Change-4.14%
Aug-04-20 07:35AM  
Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million
ACCESSWIRE
07:30AM  
Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics
ACCESSWIRE
Jul-20-20 07:30AM  
Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12
ACCESSWIRE
Jul-15-20 07:30AM  
Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference
ACCESSWIRE +10.03%
May-18-20 07:30AM  
Sonnet BioTherapeutics Holdings Provides Business and Earnings Update
ACCESSWIRE
Apr-06-20 07:30AM  
Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board
ACCESSWIRE
SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.
open in yahoo | open in reuters | open in google